August 12, 2023
To | To |
Listing Department, | The Corporate Relations Department |
NATIONAL STOCK EXCHANGE OF INDIA LIMITED | BSE LIMITED |
Exchange Plaza, | Phiroz Jeejeebhoy Towers, |
Bandra Kurla Complex, Bandra (E), | 25th floor, Dalal Street, |
MUMBAI -400 051 | MUMBAI -400 001 |
Company Code No. AUROPHARMA | Company Code No. 524804 |
Dear Sir, |
Sub: Outcome of the Board Meeting held on August 12, 2023.
The Board of Directors of the Company at its meeting held today, August 12, 2023, has inter alia, considered and approved the standalone and consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2023, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company.
The Board meeting commenced at 3.30 p.m. and concluded at 5.40 p.m.
Please take the information on record.
Yours faithfully,
For AUROBINDO PHARMA LIMITED
Digitally signed by ADIREDDY BADDIGAM
Date: 2023.08.12 17:44:48 +05'30'
B. Adi Reddy
Company Secretary
Enclosures: as above.
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: PlotNo. 2, Maithrivihar, Ameerpet, Hyderabad - 500038 T.S., INDIA Tel:+91 402373 6370/ 23747340 Fax: +914023741080/ 23746833 Email: info@aurobindo.com Website: www.aurobindo.com